Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice.

ABSTRACT: Type 2 diabetes mellitus represents a major health problem with increasing prevalence worldwide. Limited efficacy of current therapies has prompted a search for novel therapeutic options. Here we show that treatment of pre-diabetic mice with mitochondrially targeted tamoxifen, a potential anti-cancer agent with senolytic activity, improves glucose tolerance and reduces body weight with most pronounced reduction of visceral adipose tissue due to reduced food intake, suppressed adipogenesis and elimination of senescent cells. Glucose-lowering effect of mitochondrially targeted tamoxifen is linked to improvement of type 2 diabetes mellitus-related hormones profile and is accompanied by reduced lipid accumulation in liver. Lower senescent cell burden in various tissues, as well as its inhibito

SUBMITTER: Vacurova E 

PROVIDER: S-EPMC8987092 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature